Author

Colin P N Dinney

Observed names: Colin P. N. Dinney, Colin P.N. Dinney

Institutions: The University of Texas MD Anderson Cancer Center, University of Rochester Medicine, University of Rochester

Observed institutions: The University of Texas MD Anderson Cancer Center, University of Rochester Medicine, University of Rochester

OpenAlex ID: A5104978430

Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial

2024 · Elizabeth R. Plimack, Catherine Tangen, et al. · European Urology · 25

Combination treatment with intravesical interferon-alpha gene therapy and an oral pan-ErbB receptor family blocker improves survival in mice with bladder cancer

2026 · Akshay Sood, Alberto Martini, et al. · Frontiers in Molecular Biosciences

Updated results from a pilot trial of neoadjuvant durvalumb in combination with tremelimuab for cisplatin-ineligible high-risk urothelial carcinoma.

2026 · Cindy Y. Jiang, Neema Navai, et al. · Journal of Clinical Oncology

International Multicentre Analysis of Perioperative Complications Following Major Urologic Oncologic Surgery: Early Results from More than 130 000 Procedures from the CAMUS Collaborative

2026 · Christopher Soliman, Niranjan Sathianathen, et al. · European Urology Focus

Ip20-04 First Results From Core-008 Cohort Cx- Phase 2 Study of Intravesical Cretostimogene Grenadenorepvec With Gemcitabine in Patients With High-risk Bcg-exposed or Bcg-unresponsive Non-muscle Invasive Bladder Cancer

2026 · Trinity J. Bivalacqua, Aaron Berger, et al. · The Journal of Urology

The CAMUS Initiative: A Multiphase, Multicentre International Collaboration to Redefine Risk Stratification, Reporting, and Grading of Surgical Complications in Urology

2026 · Christopher Soliman, Niranjan J. Sathianathen, et al. · European Urology Open Science

Topline results from BOND-003 cohort P: A multi-national, single-arm study of intravesical cretostimogene grenadenorepvec for treatment of high-risk, papillary only, BCG-unresponsive non-muscle invasive bladder cancer.

2026 · Siamak Daneshmand, Paras H. Shah, et al. · Journal of Clinical Oncology

Combination Treatment with Intravesical Interferon-Alpha Gene Therapy and Oral Pan-ErbB Receptor Family Blocker Improves Survival in Mice with Bladder Cancer

2026 · Akshay Sood, Alberto Martini, et al. · bioRxiv (Cold Spring Harbor Laboratory)

Works count: 8

Citation count: 25

H-index: 1

I10-index: 1